Insmed reported $2.08B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Cytokinetics USD 1.27B 151.06M Mar/2026
DBV Technologies USD 223.2M 43.2M Jun/2026
Gilead Sciences USD 49.36B 6.92B Jun/2026
Heron Therapeutics USD 246.22M 9.66M Mar/2026
Insmed USD 2.08B 188.7M Mar/2026
Novartis USD 118.53B 7.58B Mar/2026
Regeneron Pharmaceuticals USD 41.73B 861.8M Jun/2026
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
Ultragenyx Pharmaceutical USD 1.26B 32M Jun/2026
Vertex Pharmaceuticals USD 27.42B 938.9M Jun/2026